Waiv Secures $33 Million to Revolutionize Cancer Diagnostics with AI
March 13, 2026, 9:39 am
Waiv, an AI precision testing innovator, recently secured $33 million in funding. This Paris-based company spun out from Owkin. It transforms cancer diagnostics. Waiv's powerful AI analyzes digital histopathology and multimodal clinical data. This identifies optimal patient treatments, accelerating therapeutic development. Waiv aims to improve global cancer care. It expands precision medicine access. Products like RlapsRisk BC and MSIntuit Suite already impact clinical settings. The company promises a new era for oncology, fueled by this strategic investment and international expansion plans.
Waiv is reshaping cancer care. The company, a pioneer in AI-powered precision testing, announced a significant financial boost. It closed a $33 million funding round. This investment propels Waiv into a new phase. It spun out from AI biotech giant Owkin.
The financing round saw strong participation. OTB Ventures and Alpha Intelligence Capital co-led the investment. Serena Data Ventures, Karista, and SistaFund also joined. This capital injection underscores investor confidence. Waiv's mission is clear: make AI-enabled precision testing the global standard in oncology.
Waiv utilizes advanced artificial intelligence. Its platform processes vast amounts of clinical data. This includes digital histopathology slides. It also integrates multimodal clinical information. The AI extracts hidden biological signals. These signals guide crucial treatment decisions. This approach enables faster, more accurate patient stratification. It refines therapy selection.
Traditional cancer diagnostics face challenges. They are often slow. They can be less precise. Waiv's technology bypasses these limitations. It converts routine pathology into high-resolution maps of disease biology. This offers unprecedented insights. Clinicians can identify which treatments will work best. Patients receive more targeted, effective care. This personalized approach is the future of medicine.
Waiv's solutions are already deployed. They operate in active clinical settings. Its product portfolio demonstrates tangible benefits.
RlapsRisk BC is one such offering. This prognostic risk profiling test targets breast cancer. It helps doctors assess patient risk. This informs treatment pathways.
MSIntuit Suite tackles microsatellite instability (MSI). MSI detection is vital for certain cancer therapies. Waiv’s AI streamlines this complex process. It identifies MSI-enriched patient populations efficiently. This ensures appropriate treatment selection. Waiv partnered with MSD on this initiative.
BRCAura provides another critical tool. It's an AI-based pre-screen test. BRCA mutations are linked to several cancers. BRCAura identifies germline BRCA mutations from pathology slides. This accelerates genetic screening. AstraZeneca also collaborates on an AI-driven gBRCA pre-screen.
These technologies enhance patient testing. They improve stratification accuracy. Diagnostic workflows become more streamlined. Access to precision medicine expands dramatically. Waiv turns routinely generated data into actionable biology.
The $33 million funding fuels ambitious expansion. Waiv plans to broaden its portfolio. It will add more clinical-grade multimodal tests. Integrations with pharmaceutical R&D pipelines will deepen. This supports drug development and biomarker discovery.
Global market access is a primary objective. Waiv aims to reach more laboratories. It seeks to empower healthcare providers worldwide. The goal is widespread adoption of its diagnostic solutions. This means greater speed and scalability in oncology testing. Drug developers gain access to previously unobtainable insights.
Meriem Sefta leads Waiv as CEO. She envisions AI transforming oncology. The company's unique AI tech stack leverages advanced foundation models. These models provide generalizability. They offer scalability across diverse clinical settings. This technological maturity is what oncology needs.
Waiv’s independence does not sever its roots. It remains closely integrated with Owkin's patient validation ecosystem. Owkin, a leader in medical AI research, built Waiv's foundational technology. This decade of research provides a robust base.
Waiv benefits from Owkin’s extensive patient data network. It also utilizes proprietary AI models. These models are trained on multimodal data. This access is a competitive advantage.
Owkin's ecosystem includes patient-derived organoid testing. It encompasses Owkin’s therapeutic clinical trial INVOKE. INVOKE targets triple inhibition of EP2, EP4, and DP1. This creates a powerful feedback loop. AI models undergo validation through real-world clinical application. Computational insights convert into clinically validated intellectual property.
The new capital enables critical advancements. Waiv will accelerate global deployment of its platform. It ensures more patients benefit from AI-enabled precision testing. The company's Destra platform integrates directly into existing laboratory workflows. Clinicians can run Waiv’s diagnostic tests seamlessly. No operational system changes are needed.
Precision medicine demands reliable patient matching. Therapies must align with individual needs. Achieving this remains complex. Waiv simplifies this complexity. It brings AI's speed and scalability to oncology. It enables personalized, efficient, and outcome-focused medicine.
Waiv's platform combines key elements. Large-scale multimodal datasets are crucial. Proprietary AI models provide intelligence. Clinical validation capabilities ensure reliability. All are integrated into a single stack. This comprehensive approach sets Waiv apart. It promises a paradigm shift in how cancer is understood and treated. The future of oncology is intelligent. It is precise. It is Waiv.
Waiv is reshaping cancer care. The company, a pioneer in AI-powered precision testing, announced a significant financial boost. It closed a $33 million funding round. This investment propels Waiv into a new phase. It spun out from AI biotech giant Owkin.
The financing round saw strong participation. OTB Ventures and Alpha Intelligence Capital co-led the investment. Serena Data Ventures, Karista, and SistaFund also joined. This capital injection underscores investor confidence. Waiv's mission is clear: make AI-enabled precision testing the global standard in oncology.
The Power of Precision AI
Waiv utilizes advanced artificial intelligence. Its platform processes vast amounts of clinical data. This includes digital histopathology slides. It also integrates multimodal clinical information. The AI extracts hidden biological signals. These signals guide crucial treatment decisions. This approach enables faster, more accurate patient stratification. It refines therapy selection.
Traditional cancer diagnostics face challenges. They are often slow. They can be less precise. Waiv's technology bypasses these limitations. It converts routine pathology into high-resolution maps of disease biology. This offers unprecedented insights. Clinicians can identify which treatments will work best. Patients receive more targeted, effective care. This personalized approach is the future of medicine.
Proven Clinical Impact
Waiv's solutions are already deployed. They operate in active clinical settings. Its product portfolio demonstrates tangible benefits.
RlapsRisk BC is one such offering. This prognostic risk profiling test targets breast cancer. It helps doctors assess patient risk. This informs treatment pathways.
MSIntuit Suite tackles microsatellite instability (MSI). MSI detection is vital for certain cancer therapies. Waiv’s AI streamlines this complex process. It identifies MSI-enriched patient populations efficiently. This ensures appropriate treatment selection. Waiv partnered with MSD on this initiative.
BRCAura provides another critical tool. It's an AI-based pre-screen test. BRCA mutations are linked to several cancers. BRCAura identifies germline BRCA mutations from pathology slides. This accelerates genetic screening. AstraZeneca also collaborates on an AI-driven gBRCA pre-screen.
These technologies enhance patient testing. They improve stratification accuracy. Diagnostic workflows become more streamlined. Access to precision medicine expands dramatically. Waiv turns routinely generated data into actionable biology.
Strategic Growth and Global Reach
The $33 million funding fuels ambitious expansion. Waiv plans to broaden its portfolio. It will add more clinical-grade multimodal tests. Integrations with pharmaceutical R&D pipelines will deepen. This supports drug development and biomarker discovery.
Global market access is a primary objective. Waiv aims to reach more laboratories. It seeks to empower healthcare providers worldwide. The goal is widespread adoption of its diagnostic solutions. This means greater speed and scalability in oncology testing. Drug developers gain access to previously unobtainable insights.
Meriem Sefta leads Waiv as CEO. She envisions AI transforming oncology. The company's unique AI tech stack leverages advanced foundation models. These models provide generalizability. They offer scalability across diverse clinical settings. This technological maturity is what oncology needs.
Leveraging Owkin's Legacy
Waiv’s independence does not sever its roots. It remains closely integrated with Owkin's patient validation ecosystem. Owkin, a leader in medical AI research, built Waiv's foundational technology. This decade of research provides a robust base.
Waiv benefits from Owkin’s extensive patient data network. It also utilizes proprietary AI models. These models are trained on multimodal data. This access is a competitive advantage.
Owkin's ecosystem includes patient-derived organoid testing. It encompasses Owkin’s therapeutic clinical trial INVOKE. INVOKE targets triple inhibition of EP2, EP4, and DP1. This creates a powerful feedback loop. AI models undergo validation through real-world clinical application. Computational insights convert into clinically validated intellectual property.
The Future of Oncology Diagnostics
The new capital enables critical advancements. Waiv will accelerate global deployment of its platform. It ensures more patients benefit from AI-enabled precision testing. The company's Destra platform integrates directly into existing laboratory workflows. Clinicians can run Waiv’s diagnostic tests seamlessly. No operational system changes are needed.
Precision medicine demands reliable patient matching. Therapies must align with individual needs. Achieving this remains complex. Waiv simplifies this complexity. It brings AI's speed and scalability to oncology. It enables personalized, efficient, and outcome-focused medicine.
Waiv's platform combines key elements. Large-scale multimodal datasets are crucial. Proprietary AI models provide intelligence. Clinical validation capabilities ensure reliability. All are integrated into a single stack. This comprehensive approach sets Waiv apart. It promises a paradigm shift in how cancer is understood and treated. The future of oncology is intelligent. It is precise. It is Waiv.